Jason Moon
Chief Scientific Officer EVOQ Therapeutics
Seminars
Thursday 5th March 2026
Mechanistic Insights into NanoDisc-Mediated Antigen-Specific Immune Tolerance
10:00 am
- Exploring the mechanisms by which EVOQ Therapeutics’ nanoparticles induce antigen-specific immune tolerance, using multiple preclinical animal models to dissect the immunological pathways and molecular interactions underlying therapeutic efficacy
- Validating novel biomarkers to monitor immune tolerance in both preclinical and clinical contexts, establishing robust readouts that can inform translational studies and support the predictive value of preclinical models
- Discover how preclinical mechanistic insights and biomarker development can accelerate the translation of nanoparticle-based immune tolerance therapies into clinical trials, providing predictive frameworks for celiac disease and other immune-mediated conditions
